CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

被引：18
|
作者：
Agha, Mounzer E.
Cohen, Adam D.
Madduri, Deepu
Cohen, Yael C.
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Wang, Liwei
Vogel, Martin
Carrasco-Alfonso, Marlene
Akram, Muhammad
Wu, Xiaoling
Nesheiwat, Tonia
Einsele, Hermann
机构：
[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Mt Sinai Med Ctr, New York, NY 10029 USA
[4] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel
[5] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[6] Univ Ziekenhuizen Leuven, Leuven, Belgium
[7] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[8] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[9] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[10] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[11] Univ Hosp Heidelberg, Heidelberg, Germany
[12] Univ Cologne, Cologne, Germany
[13] Janssen R&D, Raritan, NJ USA
[14] Janssen Global Serv LLC, Raritan, NJ USA
[15] Legend Biotech USA Inc, Piscataway, NJ USA
[16] Legend Biotech USA Inc, Somerset, NJ USA
[17] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8013
引用
收藏
页数：3
相关论文
共 50 条
  • [31] SWASTH: Phase 1/2 Study of Ribrecabtagene Autoleucel, a BCMA-Directed CAR-T Cell Therapy, in Relapsed-Refractory Multiple Myeloma
    Menon, Hari
    Bharagava, Rahul
    Lokireddy, Padmaja
    Narayanan, Prasad
    Nataraj, K. S.
    Kumar, Akhil
    Mandavia, Divyesh
    Ramachandra, Murali
    Mathews, Vikram
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S65 - S65
  • [32] Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (ciltacel) in lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 Cohort A
    Cohen, Adam
    Einsele, Hermann
    Delforge, Michel
    Hillengass, Jens
    Goldschmidt, Hartmut
    Weisel, Katja
    Raab, Marc-Steffen
    Scheid, Christof
    Schecter, Jordan
    De Braganca, Kevin
    Varsos, Helen
    Yeh, Tzu-min
    Mistry, Pankaj
    Roccia, Tito
    Corsale, Christina
    Akram, Muhammad
    Pacaud, Lida
    Nesheiwat, Tonia
    Agha, Mounzer
    Cohen, Yael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S27 - S28
  • [33] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-Cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results
    Einsele, H.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Cavo, M.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 120 - 121
  • [34] PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells
    Bernabei, Luca
    Garfall, Alfred L.
    Melenhorst, J. Joseph
    Lacey, Simon F.
    Stadtmauer, Edward A.
    Vogl, Dan T.
    Gonzalez, Vanessa
    Plesa, Gabriela
    Young, Regina M.
    Waxman, Adam
    Levine, Bruce L.
    June, Carl H.
    Milone, Michael C.
    Cohen, Adam D.
    BLOOD, 2018, 132
  • [35] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna E.
    Rambaldi, Alessandro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S18
  • [36] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
    Cavo, M.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I.
    Delforge, M.
    Einsele, H.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J.
    Patel, P.
    Huang, L.
    Campbell, T.
    Hege, K.
    Munshi, N.
    HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
  • [37] Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa results
    Einsele, H.
    Weisel, K.
    Goldschmidt, H.
    Munshi, N. C.
    Anderson, L. D., Jr.
    Shah, N.
    Jagannath, S.
    Berdeja, J.
    Lonial, S.
    Raje, N.
    Siegel, D. S.
    Lin, Y.
    Oriol, A.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    San Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 91
  • [38] KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma
    Usmani, Saad Z.
    Berdeja, Jesus G.
    Truppel-Hartmann, Anna
    Casadebaig, Marie-Laure
    Wortman-Vayn, Honeylet
    Shelat, Suresh G.
    Novick, Steven
    Shah, Nina
    BLOOD, 2020, 136
  • [39] Interim Phase 2 Study Results of Durcabtagene Autoleucel (PHE885), a T-Charge™ Manufactured BCMA-Directed CAR-T Cell Therapy in Patients (pts) with r/r Multiple Myeloma (RRMM)
    Spencer, Andrew
    Raab, Marc-Steffen
    Lida, Shinsuke
    Manteca, Maria-Victoria Mateos
    Cavo, Michele
    Rodriguez-Otero, Paula
    Ho, P. Joy
    Chen, Yunxin
    Ferguson, Paul
    Avivi, Irit
    Corradini, Paolo
    Chan, Esther
    Chen, Andy
    Arnulf, Bertrand
    Holtick, Udo
    Sperling, Adam
    Chu, Jufen
    Pearson, David
    Germano, Davide
    Feighery, Ronan
    Menssen, Hans
    Maier, Harald
    Dimopoulos, Meletios
    Lonial, Sagar
    Munshi, Nikhil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S8 - S9
  • [40] KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.
    Usmani, Saad Z.
    Berdeja, Jesus G.
    Truppel-Hartmann, Anna
    Fei, Yizhou
    Wortman-Vayn, Honeylet
    Shelat, Suresh
    Novick, Steven
    Shah, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345